Latest Breaking News On - Janssen scientific affairs - Page 7 : comparemela.com

New Tablet Strength Provides Additional Dosing Option for Erleada

Erleada is available as a 240mg tablet for patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.

Luca dezzaniJanssen scientific affairsVice presidentMedical affairsSolid tumor

MedEd Talks: Case-Based Conversations in Rheumatology

MedEd Talks: Case-Based Conversations in Rheumatology
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesEmily littlejohnRonalda codarioAdamj brownM elaine husniCleveland clinicclevelandLeonardh calabreseCleveland clinic foundationOffice of medical affairsJanssen scientific affairsAccreditation council for continuing medical educationAccreditation council for pharmacy educationAmerican nurses credentialing centerDepartment of rheumaticChemocentryx incMusculoskeletal center

TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was.

Spring houseBritish columbiaUnited statesCraig stoltzDermatol venereolLloyd millerSteven feldmanThompson jrJanssen biotech incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonWake forest university school of medicineAmerican academy of dermatologyEveryday healthJanssen scientific affairs

Johnson & Johnson : New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)

TITUSVILLE, NJ,March 5, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial. | March 5, 2023

United statesNew orleansMarcp bonacaKaitlin meiserLee pasqualoniMarc bonacaNone of the janssen pharmaceutical companiesDivision of cardiovascular medicineAmerican college of cardiologyUniversity of colorado anschutz medical campusJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnson

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew orleansMarcp bonacaMarc bonacaNone of the janssen pharmaceutical companiesDivision of cardiovascular medicineAmerican college of cardiologyUniversity of colorado anschutz medical campusJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionJanssen pharmaceutical companies of johnson johnsonatJanssen scientific affairsCompanies of johnson